{"id":994667,"date":"2026-08-13T07:04:11","date_gmt":"2026-08-13T11:04:11","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/parabilis-medicines-reports-second-quarter-2026-financial-results-and-provides-business-updates\/"},"modified":"2026-08-13T07:04:11","modified_gmt":"2026-08-13T11:04:11","slug":"parabilis-medicines-reports-second-quarter-2026-financial-results-and-provides-business-updates","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/parabilis-medicines-reports-second-quarter-2026-financial-results-and-provides-business-updates\/","title":{"rendered":"Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>Advanced zolucatetide across multiple Wnt\/\u03b2-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors\u00a0<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>Announced strategic research collaboration with Regeneron to develop Antibody-Helicon Conjugates, expanding application of company&#8217;s proprietary Helicon<\/em><br \/>\n        <sup><br \/>\n          <em>TM<\/em><br \/>\n        <\/sup><br \/>\n        <em> platform; received $125M in upfront consideration and equity investment, with the potential for up to $2.2B in milestone payments plus tiered royalties<\/em><br \/>\n        \n      <\/p>\n<p align=\"center\">\n        <em>Ended the second quarter with a strong financial position with $1.1B in cash, cash equivalents and marketable securities, following completion of $770.5M initial public offering and other transactions, expected to fund operations into 2030<\/em><br \/>\n        \n      <\/p>\n<p align=\"left\">CAMBRIDGE, Mass., Aug.  13, 2026  (GLOBE NEWSWIRE) &#8212; Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today reported financial results and business updates for the second quarter ended June 30, 2026.<\/p>\n<p align=\"left\">\u201cThis quarter marked meaningful progress toward our long-term vision as we continued advancing zolucatetide across multiple Wnt\/\u03b2-catenin-driven diseases, including toward planned registrational development in desmoid tumors, while also extending the reach of our Helicon\u2122 platform through our strategic research collaboration with Regeneron focused on developing Antibody-Helicon Conjugates,&#8221; said Mathai Mammen, M.D., Ph.D., Chairman, President and Chief Executive Officer of Parabilis Medicines.\u00a0<\/p>\n<p align=\"left\">Dr. Mammen continued, &#8220;The body of encouraging clinical evidence for zolucatetide has strengthened our conviction both in its potential to transform the treatment of patients with Wnt\/\u03b2-catenin-driven diseases and in the broader ability of Helicons to unlock biologically important intracellular targets that have historically been beyond the reach of conventional therapeutic approaches. With a strong balance sheet following our successful initial public offering, we believe we are well positioned to deliver important clinical and regulatory milestones over the coming quarters as we continue advancing medicines designed to target the causal biology and deliver meaningful impact for patients with serious diseases.&#8221;<\/p>\n<p align=\"left\">\n        <strong>Recent Business Highlights &amp; Anticipated Milestones\u00a0<\/strong><br \/>\n        \n      <\/p>\n<p align=\"left\">\n        <strong>Continued Advancement of Zolucatetide<\/strong><br \/>\n        <br \/>Zolucatetide is Parabilis&#8217; lead investigational Helicon and the first and only direct inhibitor of the \u03b2-catenin:TCF interaction in clinical development. The investigational therapy is being evaluated as a \u201cpipeline in a product\u201d across multiple Wnt\/\u03b2-catenin-driven diseases, with promising early clinical data demonstrating its potential in desmoid tumors, with familial adenomatous polyposis (FAP) and adamantinomatous craniopharyngioma (ACP) as potential genetically anchored expansion opportunities. <\/p>\n<p align=\"left\">\n        <em>Desmoid tumors<\/em>\n      <\/p>\n<ul type=\"disc\">\n<li>Abstract accepted for oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026 (Oct. 23-27, Madrid), with a plan to share clinical data from the February data cut from the ongoing Phase 1\/2 study of zolucatetide in desmoid tumor patients<\/li>\n<li>Expect to present more mature clinical data from the ongoing Phase 1\/2 study in desmoid tumors during the fourth quarter of 2026<\/li>\n<li>Expect to engage with the U.S. Food and Drug Administration (FDA) during the fourth quarter of 2026 to discuss and align on the planned registrational Phase 3 trial<\/li>\n<li>On track to initiate Phase 3 registrational trial in the first half of 2027\n<\/li>\n<\/ul>\n<p>\n        <em>Familial adenomatous polyposis (FAP)<\/em>\n      <\/p>\n<ul type=\"disc\">\n<li>Expect to initiate enrollment in a dedicated clinical cohort evaluating zolucatetide in patients with FAP during the second half of 2026<\/li>\n<li>Anticipate disclosing additional FAP data in the first quarter of 2027\n<\/li>\n<\/ul>\n<p>\n        <em>Adamantinomatous craniopharyngioma (ACP) <\/em>\n      <\/p>\n<ul type=\"disc\">\n<li>Expect to share clinical data from additional patients in the first half of 2027 for ACP, a locally aggressive tumor arising near the pituitary gland associated with significant lifelong morbidity and no approved drug therapies, with a conservatively estimated 15-year prevalence of approximately 5,000 to 9,000 patients in the U.S.\n<\/li>\n<\/ul>\n<p>\n        <em>Additional Wnt-driven tumors<\/em>\n      <\/p>\n<ul type=\"disc\">\n<li>Continue to enroll patients across additional cohorts evaluating zolucatetide across additional indications with high unmet medical need, including hepatocellular carcinoma (HCC), colorectal cancer (CRC) in rational combinations, and other Wnt-driven solid tumors<\/li>\n<li>Correspondence <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMc2517783\" rel=\"nofollow\" target=\"_blank\">published<\/a> in the <em>New England Journal of Medicine <\/em>(NEJM) demonstrates durable clinical and radiologic response to zolucatetide in a patient with recurrent ameloblastoma \u2013 a locally aggressive tumor of the jaw \u2013 driven by Wnt\/\u03b2-catenin pathway alterations, providing further clinical validation of zolucatetide&#8217;s mechanism of action\n<\/li>\n<\/ul>\n<p>\n        <strong>Expanded the Application of the Helicon Platform<\/strong><br \/>\n        <br \/>During the second quarter of 2026, Parabilis continued to expand the reach of its proprietary Helicon platform through strategic partnerships and advancement of its wholly-owned discovery pipeline.<\/p>\n<ul type=\"disc\">\n<li>\n          <a href=\"https:\/\/investors.parabilismed.com\/news-releases\/news-release-details\/parabilis-medicines-announces-strategic-collaboration-regeneron\" rel=\"nofollow\" target=\"_blank\">Announced<\/a> a strategic collaboration with Regeneron Pharmaceuticals, Inc. focused on developing Antibody-Helicon Conjugates (AHCs), a novel therapeutic modality combining Regeneron&#8217;s VelocImmune\u00ae antibody technologies with Parabilis&#8217; proprietary Helicon platform to selectively target undruggable and challenging intracellular disease-driving proteins; Parabilis received $125 million, including $50 million in upfront consideration and a $75 million equity investment, and the collaboration provides the potential for up to approximately $2.2 billion in development, regulatory and commercial milestone payments, plus up to low double-digit tiered royalties<\/li>\n<li>Continued advancing multiple wholly owned Helicon-based preclinical programs targeting historically undruggable intracellular proteins, including ERG and allosteric AR<sup>ON<\/sup> degraders in prostate cancer and a \u03b2-catenin degrader program\n<\/li>\n<\/ul>\n<p>\n        <strong>Strengthened Leadership and Governance<\/strong><br \/>\n        <br \/>Parabilis continued to strengthen its leadership team and Board of Directors to support the Company&#8217;s next phase of growth as a public company.<\/p>\n<ul type=\"disc\">\n<li>\n          <a href=\"https:\/\/investors.parabilismed.com\/news-releases\/news-release-details\/parabilis-medicines-expands-executive-leadership-team\" rel=\"nofollow\" target=\"_blank\">Expanded<\/a> the Company\u2019s executive leadership team through the appointments of Helen Ho, Ph.D., as Chief Business &amp; Strategy Officer, and Tom Kotarakos as Chief Financial Officer<\/li>\n<li>\n          <a href=\"https:\/\/investors.parabilismed.com\/news-releases\/news-release-details\/parabilis-medicines-appoints-biopharmaceutical-finance-leader\" rel=\"nofollow\" target=\"_blank\">Appointed<\/a> Alan M. Sebulsky\u00a0to the Board of Directors, bringing more than three decades of biopharmaceutical finance and operational leadership experience<\/p>\n<\/li>\n<\/ul>\n<p>\n        <strong>Completed Initial Public Offering<\/strong><br \/>\n        <br \/>During the quarter, Parabilis successfully <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KFqeZlItTxk0oeFvgNsIRULMXiYLkoqcTDjEVrcc6UzVLloo1ZH4l8k2Ag_Hk0T-IicMQDPJu4XeduoJndeH90fWx2bQ_rh3dMByruSRFLcnJ0kZo8PIwuYDPp0RAIIdI1zBNWpIfv1U8zqgUmwW0fUtHiGBc4OqDaK0SKEJMA_k6-C1UofcNy5ZMFo2NxbLYQct20IwWpBstchsydHMwZ-XCqniPTCPMEvO3V6gIvA=\" rel=\"nofollow\" target=\"_blank\">completed<\/a> its upsized initial public offering, raising a total of $770.5 million (before offering expenses), strengthening the Company&#8217;s balance sheet to support the continued advancement of its clinical pipeline and proprietary Helicon\u2122 platform.<\/p>\n<ul type=\"disc\">\n<li>Closed upsized initial public offering of common stock, including the full exercise of the underwriters&#8217; option to purchase additional shares, at an initial public offering price of\u00a0$20.00 per share<\/li>\n<li>Completed a concurrent private placement with\u00a0Regeneron resulting in gross proceeds of approximately\u00a0$75 million<\/li>\n<li>Began trading on the Nasdaq Global Select Market under the ticker symbol\u00a0&#8220;PBLS&#8221;\u00a0on\u00a0June 10, 2026\n<\/li>\n<\/ul>\n<p>\n        <strong>Second Quarter Financial Results<\/strong><br \/>\n        <br \/>\n        <strong>Cash position<\/strong>: Cash, cash equivalents and marketable securities were $1.1 billion as of June 30, 2026, compared to $27.7 million as of December 31, 2025. The Company&#8217;s cash, cash equivalents and marketable securities as of June 30, 2026 are expected to fund its operations into 2030.<\/p>\n<p>\n        <strong>R&amp;D expenses<\/strong>: Research and development expenses were $39.4 million for the quarter ended June 30, 2026, compared to $30.1 million for the comparable prior year period. The increase of $9.3 million was primarily driven by ongoing investment in the clinical development of zolucatetide across a number of indications, increased employee-related costs (including stock-based compensation) associated with increased hiring to support the advancing clinical pipeline, and progression of the Company\u2019s preclinical \u03b2-catenin, ERG, and AR<sup>ON<\/sup> degrader programs.<\/p>\n<p>\n        <strong>G&amp;A expenses<\/strong>: General and administrative expenses were $11.7 million for the quarter ended June 30, 2026, compared to $6.4 million for the comparable prior year period. The increase of $5.3 million was primarily due to higher employee-related costs (including stock-based compensation) related to increased hiring to support the Company&#8217;s growth as it advances its clinical programs, and expenses associated with operating as a public company.<\/p>\n<p>\n        <strong>Net loss<\/strong>: Net loss was $52.5 million for the quarter ended June 30, 2026, compared to $34.8 million for the comparable prior year period. The increase in net loss of $17.7 million was primarily driven by increased operating expenses.<\/p>\n<p>\n        <strong>About Parabilis Medicines\u00a0<\/strong><br \/>\n        <br \/>Parabilis Medicines (Nasdaq: PBLS) is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking biologically important targets long\u00a0considered undruggable.\u00a0The company has pioneered a new class of alpha-helical peptides \u2013 Helicons\u2122 \u2013 capable of modulating intracellular proteins that have historically been beyond the reach of conventional medicines. The company\u2019s lead investigational\u00a0medicine, zolucatetide, is the first and only direct inhibitor\u00a0of the\u00a0\u03b2-catenin:TCF\u00a0interaction,\u00a0a central node in the Wnt\/\u03b2-catenin pathway that has\u00a0eluded drug developers\u00a0for decades. Zolucatetide\u00a0is being evaluated in the clinic across multiple Wnt\/\u03b2-catenin-driven diseases, including desmoid tumors, familial adenomatous polyposis (FAP), adamantinomatous craniopharyngioma (ACP) and a range of\u00a0other\u00a0solid tumor indications. Beyond\u00a0zolucatetide, Parabilis\u00a0is advancing additional Helicon-based\u00a0programs focused on other challenging targets\u00a0where we believe\u00a0our\u00a0medicines could have life-altering impact. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EqBLtKCm-OFT3G_qKTvRsWG4_zVbyCLLi5LceswDKP9Q3MSM-sZZ1s-zF9q0HBZiBB1HOqfI1d_gMF1dRK1XuveNqnN2m7UwdaoB3uwtGd2cSgCVzzpmk9LOnKBl3qkjo4HgoxTCnNqueoKlE8Ts2_m2yC5XD9kMZhTYY4gdcRxXexcjvNoO8xWzts8lbQj9\" rel=\"nofollow\" target=\"_blank\">www.parabilismed.com<\/a>\u00a0or follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OVAo02FLIiRamQhi5KTyzi_vo-4XqjOIArVqJQRDPaIvxq5XTrDwh3AbHLHVR5mhGIT2tgWQrDId8AMXF0jzjDRTkro_o33uXu0nqlYKF6J7k5HNIwLFDXYlvwfw69Slk68SdwjpD5CaU3qnEos2gpa8CCnqYVfKpeOmqQQekhE=\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. The words \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwould\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding: the clinical development of zolucatetide for the treatment of desmoid tumors, FAP, ACP and other rare, Wnt-driven tumors, including the initiation, timing, progress, results and future data releases of our ongoing and planned clinical trials; the expected initiation and timing of the Company\u2019s planned Phase 3 registrational trial in desmoid tumors; the expected timing and results of the ongoing Phase 1\/2 study in desmoid tumors; the expected enrollment and timing of certain patient cohorts in Wnt-driven tumors; the expected timing and results of and anticipated payments under the Company\u2019s collaboration agreement with Regeneron; the expected timing and results of the Company\u2019s preclinical development of its ERG degrader, AR<sup>ON<\/sup> degrader and \u03b2-catenin degrader development candidates; the potential of the Company\u2019s Helicon\u2122 technology platform; expectations regarding the development of any future product candidates using the Company\u2019s Helicon\u2122 technology platform; expectations regarding the efficacy, tolerability, and commercial potential of zolucatetide; and expectations for the Company\u2019s uses of capital, expenses and financial results, including its cash runway into 2030.<\/p>\n<p>Any forward-looking statements in this press release are based on management\u2019s current expectations and beliefs and are subject to a number of risks and uncertainties that could negatively affect the Company\u2019s business, operating results, financial condition and stock value. Factors that could cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release include, without limitation: risks relating to the Company\u2019s research and development activities; the Company\u2019s ability to execute on its strategy including obtaining the requisite regulatory approvals on the expected timeline, if at all; uncertainties relating to preclinical and clinical development activities; the Company\u2019s dependence on third parties to conduct clinical trials, manufacture its product candidates and develop and commercialize its product candidates, if approved; the Company\u2019s ability to attract, integrate and retain key personnel; risks related to the Company\u2019s financial condition and need for substantial additional funds in order to complete development activities and commercialize a product candidate, if approved; risks related to regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities; risks related to establishing and maintaining the Company\u2019s intellectual property protections; and risks related to the competitive landscape for the Company\u2019s product candidates; as well as other risks and uncertainties described in greater detail in \u201cRisk Factors,\u201d in the Company\u2019s most recent Quarterly Report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in the Company\u2019s subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent the Company\u2019s views only as of today and should not be relied upon as representing its views as of any subsequent date. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.<\/p>\n<p>\n        <strong>Media Contact<\/strong><br \/>\n        <br \/>Jessica Freifeld<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Iko9nuEWx5izVjzlw0pEtUR2_KQKNNbpqGVP1S0LTYEmFd6kUDYYlOo2xrqnP329phKu59fwp8Is6WDefFswHtEY3yePE1PiJm51dO1Czkc=\" rel=\"nofollow\" target=\"_blank\">media@parabilismed.com<\/a><\/p>\n<p><strong>Investor Contact: <\/strong><br \/>Tom Kotarakos<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0JtXuNFnrprlExF_MwMY1ce4Q6l3ShNl9I8e7m3pLUVxGbpIgpPDwXm-IFRluykGSYJlxVaEDWoNIz4wp3RSTm-gC_o_x_eWg3_MXcFQ-mp_Rrue_urefi9aeH0SxwjH\" rel=\"nofollow\" target=\"_blank\">investors@parabilismed.com<\/a><\/p>\n<table align=\"center\" style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"9\" style=\"width:99.9381%;text-align: center;vertical-align: middle\">\n            <strong>Parabilis Medicines, Inc. <\/strong><br \/>\n            <br \/>\n            <strong>Condensed Consolidated Balance Sheets <\/strong><br \/>\n            <br \/>\n            <strong>(in thousands)<\/strong><br \/>\n            <br \/>\n            <strong>(unaudited)<\/strong><br \/>\n            <br \/>\n            <strong><br \/>\n              <br \/>\n            <\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.2351%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:2.16584%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:11.2005%;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>June\u00a030,<\/strong>\n          <\/td>\n<td style=\"width:1.05198%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.49505%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:13.7376%;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>December\u00a031,<\/strong>\n          <\/td>\n<td style=\"width:1.05198%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.2351%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:2.16584%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:11.2005%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>2026<\/strong>\n          <\/td>\n<td style=\"width:1.05198%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.49505%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:13.7376%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>2025<\/strong>\n          <\/td>\n<td style=\"width:1.05198%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.2351%;vertical-align: top\">\n            <strong>Assets<\/strong>\n          <\/td>\n<td style=\"width:2.16584%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:11.2005%;border-top: solid black 1pt;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:1.05198%;border-top: solid black 1pt;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.49505%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:13.7376%;border-top: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.05198%;border-top: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.2351%;vertical-align: top\">Current assets:<\/td>\n<td style=\"width:2.16584%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:11.2005%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:1.05198%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.49505%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:13.7376%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.05198%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.2351%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Cash and cash equivalents<\/td>\n<td style=\"width:2.16584%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:1.54703%;vertical-align: bottom\">$<\/td>\n<td style=\"width:9.65347%;text-align: right;vertical-align: middle;vertical-align: bottom\">1,087,060<\/td>\n<td style=\"width:1.05198%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:2.04208%;vertical-align: bottom\">$<\/td>\n<td style=\"width:11.6955%;text-align: right;vertical-align: middle;vertical-align: bottom\">27,711<\/td>\n<td style=\"width:1.05198%;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.2351%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Marketable securities<\/td>\n<td style=\"width:2.16584%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:1.54703%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.65347%;text-align: right;vertical-align: middle;vertical-align: bottom\">33,637<\/td>\n<td style=\"width:1.05198%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:2.04208%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:11.6955%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:1.05198%;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.2351%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Prepaid expenses and other current assets<\/td>\n<td style=\"width:2.16584%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:1.54703%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.65347%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">4,699<\/td>\n<td style=\"width:1.05198%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:2.04208%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:11.6955%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">1,647<\/td>\n<td style=\"width:1.05198%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.2351%;vertical-align: top\">Total current assets<\/td>\n<td style=\"width:2.16584%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:1.54703%;border-top: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.65347%;border-top: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">1,125,396<\/td>\n<td style=\"width:1.05198%;border-top: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:2.04208%;border-top: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:11.6955%;border-top: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">29,358<\/td>\n<td style=\"width:1.05198%;border-top: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.2351%;vertical-align: top\">Property and equipment, net<\/td>\n<td style=\"width:2.16584%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:1.54703%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.65347%;text-align: right;vertical-align: middle;vertical-align: bottom\">6,718<\/td>\n<td style=\"width:1.05198%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:2.04208%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:11.6955%;text-align: right;vertical-align: middle;vertical-align: bottom\">6,715<\/td>\n<td style=\"width:1.05198%;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.2351%;vertical-align: top\">Restricted cash<\/td>\n<td style=\"width:2.16584%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:1.54703%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.65347%;text-align: right;vertical-align: middle;vertical-align: bottom\">2,855<\/td>\n<td style=\"width:1.05198%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:2.04208%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:11.6955%;text-align: right;vertical-align: middle;vertical-align: bottom\">2,855<\/td>\n<td style=\"width:1.05198%;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.2351%;vertical-align: top\">Operating lease right-of-use assets<\/td>\n<td style=\"width:2.16584%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:1.54703%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.65347%;text-align: right;vertical-align: middle;vertical-align: bottom\">36,007<\/td>\n<td style=\"width:1.05198%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:2.04208%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:11.6955%;text-align: right;vertical-align: middle;vertical-align: bottom\">39,360<\/td>\n<td style=\"width:1.05198%;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.2351%;vertical-align: top\">Other assets<\/td>\n<td style=\"width:2.16584%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:1.54703%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.65347%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">4,286<\/td>\n<td style=\"width:1.05198%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:2.04208%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:11.6955%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">2,532<\/td>\n<td style=\"width:1.05198%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.2351%;vertical-align: top\">Total assets<\/td>\n<td style=\"width:2.16584%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:1.54703%;border-top: solid black 1pt;border-bottom: double black 3pt;vertical-align: bottom\">$<\/td>\n<td style=\"width:9.65347%;border-top: solid black 1pt;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">1,175,262<\/td>\n<td style=\"width:1.05198%;border-top: solid black 1pt;border-bottom: double black 3pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:2.04208%;border-top: solid black 1pt;border-bottom: double black 3pt;vertical-align: bottom\">$<\/td>\n<td style=\"width:11.6955%;border-top: solid black 1pt;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">80,820<\/td>\n<td style=\"width:1.05198%;border-top: solid black 1pt;border-bottom: double black 3pt;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.2351%;vertical-align: top\">\n            <strong>Liabilities, convertible preferred stock and stockholders\u2019 equity (deficit)<\/strong>\n          <\/td>\n<td style=\"width:2.16584%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:11.2005%;border-top: double black 3pt;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:1.05198%;border-top: double black 3pt;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:13.7376%;border-top: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.05198%;border-top: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.2351%;vertical-align: top\">Current liabilities:<\/td>\n<td style=\"width:2.16584%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:11.2005%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:1.05198%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:13.7376%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.05198%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.2351%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Accounts payable<\/td>\n<td style=\"width:2.16584%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:1.54703%;vertical-align: bottom\">$<\/td>\n<td style=\"width:9.65347%;text-align: right;vertical-align: middle;vertical-align: bottom\">18,525<\/td>\n<td style=\"width:1.05198%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:2.04208%;vertical-align: bottom\">$<\/td>\n<td style=\"width:11.6955%;text-align: right;vertical-align: middle;vertical-align: bottom\">17,272<\/td>\n<td style=\"width:1.05198%;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.2351%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Accrued expenses and other current liabilities<\/td>\n<td style=\"width:2.16584%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:1.54703%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.65347%;text-align: right;vertical-align: middle;vertical-align: bottom\">19,972<\/td>\n<td style=\"width:1.05198%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:2.04208%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:11.6955%;text-align: right;vertical-align: middle;vertical-align: bottom\">18,630<\/td>\n<td style=\"width:1.05198%;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.2351%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Operating lease liabilities, current portion<\/td>\n<td style=\"width:2.16584%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:1.54703%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.65347%;text-align: right;vertical-align: middle;vertical-align: bottom\">7,592<\/td>\n<td style=\"width:1.05198%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:2.04208%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:11.6955%;text-align: right;vertical-align: middle;vertical-align: bottom\">7,174<\/td>\n<td style=\"width:1.05198%;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.2351%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Deferred revenue, current portion<\/td>\n<td style=\"width:2.16584%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:1.54703%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.65347%;text-align: right;vertical-align: middle;vertical-align: bottom\">10,371<\/td>\n<td style=\"width:1.05198%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:2.04208%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:11.6955%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:1.05198%;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.2351%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Finance lease liabilities, current portion<\/td>\n<td style=\"width:2.16584%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:1.54703%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.65347%;text-align: right;vertical-align: middle;vertical-align: bottom\">669<\/td>\n<td style=\"width:1.05198%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:2.04208%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:11.6955%;text-align: right;vertical-align: middle;vertical-align: bottom\">638<\/td>\n<td style=\"width:1.05198%;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.2351%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Term loan, net of discount<\/td>\n<td style=\"width:2.16584%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:1.54703%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.65347%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">5,710<\/td>\n<td style=\"width:1.05198%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:2.04208%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:11.6955%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">13,077<\/td>\n<td style=\"width:1.05198%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.2351%;vertical-align: top\">Total current liabilities<\/td>\n<td style=\"width:2.16584%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:1.54703%;border-top: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.65347%;border-top: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">62,839<\/td>\n<td style=\"width:1.05198%;border-top: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:2.04208%;border-top: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:11.6955%;border-top: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">56,791<\/td>\n<td style=\"width:1.05198%;border-top: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.2351%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Operating lease liabilities, net of current portion<\/td>\n<td style=\"width:2.16584%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:1.54703%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.65347%;text-align: right;vertical-align: middle;vertical-align: bottom\">32,413<\/td>\n<td style=\"width:1.05198%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:2.04208%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:11.6955%;text-align: right;vertical-align: middle;vertical-align: bottom\">36,341<\/td>\n<td style=\"width:1.05198%;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.2351%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Finance lease liabilities, net of current portion<\/td>\n<td style=\"width:2.16584%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:1.54703%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.65347%;text-align: right;vertical-align: middle;vertical-align: bottom\">1,128<\/td>\n<td style=\"width:1.05198%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:2.04208%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:11.6955%;text-align: right;vertical-align: middle;vertical-align: bottom\">1,470<\/td>\n<td style=\"width:1.05198%;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.2351%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Deferred revenue, net of current portion<\/td>\n<td style=\"width:2.16584%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:1.54703%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.65347%;text-align: right;vertical-align: middle;vertical-align: bottom\">31,148<\/td>\n<td style=\"width:1.05198%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:2.04208%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:11.6955%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:1.05198%;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.2351%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Other liabilities<\/td>\n<td style=\"width:2.16584%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:1.54703%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.65347%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:1.05198%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:2.04208%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:11.6955%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">2,742<\/td>\n<td style=\"width:1.05198%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.2351%;vertical-align: top\">Total liabilities<\/td>\n<td style=\"width:2.16584%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:1.54703%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.65347%;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">127,528<\/td>\n<td style=\"width:1.05198%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:2.04208%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:11.6955%;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">97,344<\/td>\n<td style=\"width:1.05198%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.2351%;vertical-align: top\">Commitments and contingencies<\/td>\n<td style=\"width:2.16584%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:11.2005%;border-top: solid black 1pt;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:1.05198%;border-top: solid black 1pt;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:13.7376%;border-top: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.05198%;border-top: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.2351%;vertical-align: top\">Convertible preferred stock<\/td>\n<td style=\"width:2.16584%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:1.54703%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.65347%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:1.05198%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:2.04208%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:11.6955%;text-align: right;vertical-align: middle;vertical-align: bottom\">509,971<\/td>\n<td style=\"width:1.05198%;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.2351%;vertical-align: top\">Stockholders\u2019 equity (deficit):<\/td>\n<td style=\"width:2.16584%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:11.2005%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:1.05198%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:13.7376%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.05198%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.2351%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Preferred stock<\/td>\n<td style=\"width:2.16584%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:1.54703%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.65347%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:1.05198%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:2.04208%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:11.6955%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:1.05198%;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.2351%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Common stock<\/td>\n<td style=\"width:2.16584%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:1.54703%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.65347%;text-align: right;vertical-align: middle;vertical-align: bottom\">12<\/td>\n<td style=\"width:1.05198%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:2.04208%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:11.6955%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:1.05198%;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.2351%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Non-voting common stock<\/td>\n<td style=\"width:2.16584%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:1.54703%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.65347%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:1.05198%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:2.04208%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:11.6955%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:1.05198%;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.2351%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Additional paid-in capital<\/td>\n<td style=\"width:2.16584%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:1.54703%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:9.65347%;text-align: right;vertical-align: middle;vertical-align: top\">1,687,023<\/td>\n<td style=\"width:1.05198%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:2.04208%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:11.6955%;text-align: right;vertical-align: middle;vertical-align: bottom\">15,009<\/td>\n<td style=\"width:1.05198%;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.2351%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Accumulated other comprehensive loss<\/td>\n<td style=\"width:2.16584%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:1.54703%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:9.65347%;text-align: right;vertical-align: middle;vertical-align: top\">(18<\/td>\n<td style=\"width:1.05198%;vertical-align: top\">)<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:2.04208%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:11.6955%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:1.05198%;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.2351%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Accumulated deficit<\/td>\n<td style=\"width:2.16584%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:1.54703%;border-bottom: solid black 1pt;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:9.65347%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: top\">(639,283<\/td>\n<td style=\"width:1.05198%;border-bottom: solid black 1pt;vertical-align: top\">)<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:2.04208%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:11.6955%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(541,504<\/td>\n<td style=\"width:1.05198%;border-bottom: solid black 1pt;vertical-align: bottom\">)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.2351%;vertical-align: top\">Total stockholders\u2019 equity (deficit)<\/td>\n<td style=\"width:2.16584%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:1.54703%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.65347%;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">1,047,734<\/td>\n<td style=\"width:1.05198%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:2.04208%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:11.6955%;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(526,495<\/td>\n<td style=\"width:1.05198%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.2351%;vertical-align: top\">Total liabilities, convertible preferred stock and stockholders\u2019 equity (deficit)<\/td>\n<td style=\"width:2.16584%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:1.54703%;border-top: solid black 1pt;border-bottom: double black 3pt;vertical-align: bottom\">$<\/td>\n<td style=\"width:9.65347%;border-top: solid black 1pt;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">1,175,262<\/td>\n<td style=\"width:1.05198%;border-top: solid black 1pt;border-bottom: double black 3pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:2.04208%;border-top: solid black 1pt;border-bottom: double black 3pt;vertical-align: bottom\">$<\/td>\n<td style=\"width:11.6955%;border-top: solid black 1pt;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">80,820<\/td>\n<td style=\"width:1.05198%;border-top: solid black 1pt;border-bottom: double black 3pt;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.2351%\">\u00a0<\/td>\n<td style=\"width:2.16584%\">\u00a0<\/td>\n<td style=\"width:1.54703%\">\u00a0<\/td>\n<td style=\"width:9.65347%\">\u00a0<\/td>\n<td style=\"width:1.05198%\">\u00a0<\/td>\n<td style=\"width:0.49505%\">\u00a0<\/td>\n<td style=\"width:2.04208%\">\u00a0<\/td>\n<td style=\"width:11.6955%\">\u00a0<\/td>\n<td style=\"width:1.05198%\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p align=\"center\">\n        \n      <\/p>\n<table align=\"center\" style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"17\" style=\"width:100%;text-align: center;vertical-align: middle\">\n            <strong>Parabilis Medicines, Inc.<\/strong><br \/>\n            <br \/>\n            <strong>Condensed Consolidated Statements of Operations and Comprehensive Loss <\/strong><br \/>\n            <br \/>\n            <strong>(in thousands, except share and per share amounts) <\/strong><br \/>\n            <br \/>\n            <strong>(unaudited)<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"width:50.1238%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.433168%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"6\" style=\"width:24.6906%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>Three Months Ended June\u00a030,<\/strong>\n          <\/td>\n<td style=\"width:0.866337%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.433168%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"6\" style=\"width:22.5248%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>Six Months Ended June\u00a030,<\/strong>\n          <\/td>\n<td style=\"width:0.928218%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:50.1238%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.433168%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:12.3144%;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>2026<\/strong>\n          <\/td>\n<td style=\"width:1.05198%;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.49505%;border-top: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:10.8292%;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>2025<\/strong>\n          <\/td>\n<td style=\"width:0.866337%;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.433168%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:11.0767%;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>2026<\/strong>\n          <\/td>\n<td style=\"width:0.990099%;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.433168%;border-top: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:10.0248%;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>2025<\/strong>\n          <\/td>\n<td style=\"width:0.928218%;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:50.1238%;vertical-align: top\">Collaboration revenue<\/td>\n<td style=\"width:0.433168%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.54703%;border-top: solid black 1pt;vertical-align: bottom\">$<\/td>\n<td style=\"width:10.7673%;border-top: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">148<\/td>\n<td style=\"width:1.05198%;border-top: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.54703%;border-top: solid black 1pt;vertical-align: bottom\">$<\/td>\n<td style=\"width:9.28218%;border-top: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:0.866337%;border-top: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.36139%;border-top: solid black 1pt;vertical-align: bottom\">$<\/td>\n<td style=\"width:9.71535%;border-top: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">148<\/td>\n<td style=\"width:0.990099%;border-top: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.36139%;border-top: solid black 1pt;vertical-align: bottom\">$<\/td>\n<td style=\"width:8.66337%;border-top: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:0.928218%;border-top: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:50.1238%;vertical-align: top\">Operating expenses:<\/td>\n<td style=\"width:0.433168%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:12.3144%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.05198%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:10.8292%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.866337%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:11.0767%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.990099%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:10.0248%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.928218%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:50.1238%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Research and development<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.54703%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.7673%;text-align: right;vertical-align: middle;vertical-align: bottom\">39,377<\/td>\n<td style=\"width:1.05198%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.54703%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.28218%;text-align: right;vertical-align: middle;vertical-align: bottom\">30,126<\/td>\n<td style=\"width:0.866337%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.36139%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.71535%;text-align: right;vertical-align: middle;vertical-align: bottom\">77,130<\/td>\n<td style=\"width:0.990099%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.36139%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:8.66337%;text-align: right;vertical-align: middle;vertical-align: bottom\">64,031<\/td>\n<td style=\"width:0.928218%;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:50.1238%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">General and administrative<\/td>\n<td style=\"width:0.433168%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.54703%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.7673%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">11,657<\/td>\n<td style=\"width:1.05198%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.54703%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.28218%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">6,394<\/td>\n<td style=\"width:0.866337%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.36139%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.71535%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">21,357<\/td>\n<td style=\"width:0.990099%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.36139%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:8.66337%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">12,730<\/td>\n<td style=\"width:0.928218%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:50.1238%;vertical-align: top\">Total operating expenses<\/td>\n<td style=\"width:0.433168%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.54703%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.7673%;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">51,034<\/td>\n<td style=\"width:1.05198%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.54703%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.28218%;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">36,520<\/td>\n<td style=\"width:0.866337%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.36139%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.71535%;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">98,487<\/td>\n<td style=\"width:0.990099%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.36139%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:8.66337%;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">76,761<\/td>\n<td style=\"width:0.928218%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:50.1238%;vertical-align: top\">Loss from operations<\/td>\n<td style=\"width:0.433168%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.54703%;border-top: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.7673%;border-top: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(50,886<\/td>\n<td style=\"width:1.05198%;border-top: solid black 1pt;vertical-align: bottom\">)<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.54703%;border-top: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.28218%;border-top: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(36,520<\/td>\n<td style=\"width:0.866337%;border-top: solid black 1pt;vertical-align: bottom\">)<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.36139%;border-top: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.71535%;border-top: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(98,339<\/td>\n<td style=\"width:0.990099%;border-top: solid black 1pt;vertical-align: bottom\">)<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.36139%;border-top: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:8.66337%;border-top: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(76,761<\/td>\n<td style=\"width:0.928218%;border-top: solid black 1pt;vertical-align: bottom\">)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:50.1238%;vertical-align: top\">Other income (expense):<\/td>\n<td style=\"width:0.433168%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:12.3144%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.05198%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:10.8292%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.866337%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:11.0767%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.990099%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:10.0248%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.928218%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:50.1238%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Interest income<\/td>\n<td style=\"width:0.433168%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.54703%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.7673%;text-align: right;vertical-align: middle;vertical-align: bottom\">4,189<\/td>\n<td style=\"width:1.05198%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.54703%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.28218%;text-align: right;vertical-align: middle;vertical-align: bottom\">1,049<\/td>\n<td style=\"width:0.866337%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.36139%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.71535%;text-align: right;vertical-align: middle;vertical-align: bottom\">6,618<\/td>\n<td style=\"width:0.990099%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.36139%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:8.66337%;text-align: right;vertical-align: middle;vertical-align: bottom\">2,306<\/td>\n<td style=\"width:0.928218%;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:50.1238%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Interest expense<\/td>\n<td style=\"width:0.433168%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.54703%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.7673%;text-align: right;vertical-align: middle;vertical-align: bottom\">(210<\/td>\n<td style=\"width:1.05198%;vertical-align: bottom\">)<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.54703%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.28218%;text-align: right;vertical-align: middle;vertical-align: bottom\">(396<\/td>\n<td style=\"width:0.866337%;vertical-align: bottom\">)<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.36139%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.71535%;text-align: right;vertical-align: middle;vertical-align: bottom\">(502<\/td>\n<td style=\"width:0.990099%;vertical-align: bottom\">)<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.36139%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:8.66337%;text-align: right;vertical-align: middle;vertical-align: bottom\">(795<\/td>\n<td style=\"width:0.928218%;vertical-align: bottom\">)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:50.1238%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Sublease income &#8211; related party<\/td>\n<td style=\"width:0.433168%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.54703%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.7673%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:1.05198%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.54703%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.28218%;text-align: right;vertical-align: middle;vertical-align: bottom\">1,057<\/td>\n<td style=\"width:0.866337%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.36139%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.71535%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:0.990099%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.36139%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:8.66337%;text-align: right;vertical-align: middle;vertical-align: bottom\">2,114<\/td>\n<td style=\"width:0.928218%;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:50.1238%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Change in fair value of simple agreement for future equity<\/td>\n<td style=\"width:0.433168%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.54703%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.7673%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(5,556<\/td>\n<td style=\"width:1.05198%;border-bottom: solid black 1pt;vertical-align: bottom\">)<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.54703%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.28218%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:0.866337%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.36139%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.71535%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(5,556<\/td>\n<td style=\"width:0.990099%;border-bottom: solid black 1pt;vertical-align: bottom\">)<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.36139%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:8.66337%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:0.928218%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:50.1238%;vertical-align: top\">Total other (expense) income, net<\/td>\n<td style=\"width:0.433168%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.54703%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.7673%;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(1,577<\/td>\n<td style=\"width:1.05198%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">)<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.54703%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.28218%;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">1,710<\/td>\n<td style=\"width:0.866337%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.36139%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.71535%;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">560<\/td>\n<td style=\"width:0.990099%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.36139%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:8.66337%;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">3,625<\/td>\n<td style=\"width:0.928218%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:50.1238%;vertical-align: top\">Net loss<\/td>\n<td style=\"width:0.433168%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.54703%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">$<\/td>\n<td style=\"width:10.7673%;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(52,463<\/td>\n<td style=\"width:1.05198%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">)<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.54703%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">$<\/td>\n<td style=\"width:9.28218%;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(34,810<\/td>\n<td style=\"width:0.866337%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">)<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.36139%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">$<\/td>\n<td style=\"width:9.71535%;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(97,779<\/td>\n<td style=\"width:0.990099%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">)<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.36139%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">$<\/td>\n<td style=\"width:8.66337%;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(73,136<\/td>\n<td style=\"width:0.928218%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:50.1238%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Cumulative dividends on convertible preferred stock<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.54703%;border-top: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.7673%;border-top: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(14,492<\/td>\n<td style=\"width:1.05198%;border-top: solid black 1pt;vertical-align: bottom\">)<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.54703%;border-top: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.28218%;border-top: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(10,184<\/td>\n<td style=\"width:0.866337%;border-top: solid black 1pt;vertical-align: bottom\">)<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.36139%;border-top: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.71535%;border-top: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(32,181<\/td>\n<td style=\"width:0.990099%;border-top: solid black 1pt;vertical-align: bottom\">)<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.36139%;border-top: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:8.66337%;border-top: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(19,965<\/td>\n<td style=\"width:0.928218%;border-top: solid black 1pt;vertical-align: bottom\">)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:50.1238%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Deemed dividend upon down-round of convertible <br \/>preferred stock<\/td>\n<td style=\"width:0.433168%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.54703%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.7673%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:1.05198%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.54703%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.28218%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:0.866337%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.36139%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.71535%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(7,875<\/td>\n<td style=\"width:0.990099%;border-bottom: solid black 1pt;vertical-align: bottom\">)<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.36139%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:8.66337%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">\u2014<\/td>\n<td style=\"width:0.928218%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:50.1238%;vertical-align: top\">Net loss allocable to common stockholders<\/td>\n<td style=\"width:0.433168%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.54703%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">$<\/td>\n<td style=\"width:10.7673%;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(66,955<\/td>\n<td style=\"width:1.05198%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">)<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.54703%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">$<\/td>\n<td style=\"width:9.28218%;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(44,994<\/td>\n<td style=\"width:0.866337%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">)<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.36139%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">$<\/td>\n<td style=\"width:9.71535%;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(137,835<\/td>\n<td style=\"width:0.990099%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">)<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.36139%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">$<\/td>\n<td style=\"width:8.66337%;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(93,101<\/td>\n<td style=\"width:0.928218%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:50.1238%;vertical-align: top\">Net loss per share allocable to common stockholders, basic<br \/>and diluted<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.54703%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">$<\/td>\n<td style=\"width:10.7673%;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(2.32<\/td>\n<td style=\"width:1.05198%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">)<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.54703%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">$<\/td>\n<td style=\"width:9.28218%;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(22.28<\/td>\n<td style=\"width:0.866337%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">)<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.36139%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">$<\/td>\n<td style=\"width:9.71535%;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(8.86<\/td>\n<td style=\"width:0.990099%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">)<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.36139%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">$<\/td>\n<td style=\"width:8.66337%;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(46.13<\/td>\n<td style=\"width:0.928218%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:50.1238%;vertical-align: top\">Weighted average common shares outstanding, basic and diluted<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.54703%;border-top: solid black 1pt;border-bottom: double black 3pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.7673%;border-top: solid black 1pt;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">28,908,277<\/td>\n<td style=\"width:1.05198%;border-top: solid black 1pt;border-bottom: double black 3pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.54703%;border-top: solid black 1pt;border-bottom: double black 3pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.28218%;border-top: solid black 1pt;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">2,019,111<\/td>\n<td style=\"width:0.866337%;border-top: solid black 1pt;border-bottom: double black 3pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.36139%;border-top: solid black 1pt;border-bottom: double black 3pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.71535%;border-top: solid black 1pt;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">15,553,335<\/td>\n<td style=\"width:0.990099%;border-top: solid black 1pt;border-bottom: double black 3pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.36139%;border-top: solid black 1pt;border-bottom: double black 3pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:8.66337%;border-top: solid black 1pt;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">2,018,354<\/td>\n<td style=\"width:0.928218%;border-top: solid black 1pt;border-bottom: double black 3pt;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:50.1238%;vertical-align: top\">Comprehensive loss:<\/td>\n<td style=\"width:0.433168%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:12.3144%;border-top: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0\u00a0\u00a0<\/td>\n<td style=\"width:1.05198%;border-top: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:10.8292%;border-top: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0\u00a0\u00a0<\/td>\n<td style=\"width:0.866337%;border-top: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:11.0767%;border-top: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.990099%;border-top: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"width:10.0248%;border-top: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:0.928218%;border-top: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:50.1238%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Net loss<\/td>\n<td style=\"width:0.433168%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.54703%;vertical-align: bottom\">$<\/td>\n<td style=\"width:10.7673%;text-align: right;vertical-align: middle;vertical-align: bottom\">(52,463<\/td>\n<td style=\"width:1.05198%;vertical-align: bottom\">)<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.54703%;vertical-align: bottom\">$<\/td>\n<td style=\"width:9.28218%;text-align: right;vertical-align: middle;vertical-align: bottom\">(34,810<\/td>\n<td style=\"width:0.866337%;vertical-align: bottom\">)<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.36139%;vertical-align: bottom\">$<\/td>\n<td style=\"width:9.71535%;text-align: right;vertical-align: middle;vertical-align: bottom\">(97,779<\/td>\n<td style=\"width:0.990099%;vertical-align: bottom\">)<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.36139%;vertical-align: bottom\">$<\/td>\n<td style=\"width:8.66337%;text-align: right;vertical-align: middle;vertical-align: bottom\">(73,136<\/td>\n<td style=\"width:0.928218%;vertical-align: bottom\">)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:50.1238%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Change in unrealized gains (losses) on marketable <br \/>securities<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.54703%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:10.7673%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(18<\/td>\n<td style=\"width:1.05198%;border-bottom: solid black 1pt;vertical-align: bottom\">)<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.54703%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.28218%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(5<\/td>\n<td style=\"width:0.866337%;border-bottom: solid black 1pt;vertical-align: bottom\">)<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.36139%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:9.71535%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(18<\/td>\n<td style=\"width:0.990099%;border-bottom: solid black 1pt;vertical-align: bottom\">)<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.36139%;border-bottom: solid black 1pt;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:8.66337%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(21<\/td>\n<td style=\"width:0.928218%;border-bottom: solid black 1pt;vertical-align: bottom\">)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:50.1238%;vertical-align: top\">Comprehensive loss<\/td>\n<td style=\"width:0.433168%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.54703%;border-top: solid black 1pt;border-bottom: double black 3pt;vertical-align: bottom\">$<\/td>\n<td style=\"width:10.7673%;border-top: solid black 1pt;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(52,481<\/td>\n<td style=\"width:1.05198%;border-top: solid black 1pt;border-bottom: double black 3pt;vertical-align: bottom\">)<\/td>\n<td style=\"width:0.49505%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.54703%;border-top: solid black 1pt;border-bottom: double black 3pt;vertical-align: bottom\">$<\/td>\n<td style=\"width:9.28218%;border-top: solid black 1pt;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(34,815<\/td>\n<td style=\"width:0.866337%;border-top: solid black 1pt;border-bottom: double black 3pt;vertical-align: bottom\">)<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.36139%;border-top: solid black 1pt;border-bottom: double black 3pt;vertical-align: bottom\">$<\/td>\n<td style=\"width:9.71535%;border-top: solid black 1pt;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(97,797<\/td>\n<td style=\"width:0.990099%;border-top: solid black 1pt;border-bottom: double black 3pt;vertical-align: bottom\">)<\/td>\n<td style=\"width:0.433168%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.36139%;border-top: solid black 1pt;border-bottom: double black 3pt;vertical-align: bottom\">$<\/td>\n<td style=\"width:8.66337%;border-top: solid black 1pt;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(73,157<\/td>\n<td style=\"width:0.928218%;border-top: solid black 1pt;border-bottom: double black 3pt;vertical-align: bottom\">)<\/td>\n<\/tr>\n<\/table>\n<p>\n        \n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwOTIyNiM3Nzc0MTI2IzIzMTEyMTM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/N2RmODk0ODQtNWE1Mi00NjJjLTllZjUtZDI1ZDFkOTEzNjNhLTEzMjI3NjMtMjAyNi0wOC0xMy1lbg==\/tiny\/Parabilis-Medicines-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Advanced zolucatetide across multiple Wnt\/\u03b2-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors\u00a0 Announced strategic research collaboration with Regeneron to develop Antibody-Helicon Conjugates, expanding application of company&#8217;s proprietary Helicon TM platform; received $125M in upfront consideration and equity investment, with the potential for up to $2.2B in milestone payments plus tiered royalties Ended the second quarter with a strong financial position with $1.1B in cash, cash equivalents and marketable securities, following completion of $770.5M initial public offering and other transactions, expected to fund operations into 2030 CAMBRIDGE, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) &#8212; Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/parabilis-medicines-reports-second-quarter-2026-financial-results-and-provides-business-updates\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-994667","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/parabilis-medicines-reports-second-quarter-2026-financial-results-and-provides-business-updates\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Advanced zolucatetide across multiple Wnt\/\u03b2-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors\u00a0 Announced strategic research collaboration with Regeneron to develop Antibody-Helicon Conjugates, expanding application of company&#8217;s proprietary Helicon TM platform; received $125M in upfront consideration and equity investment, with the potential for up to $2.2B in milestone payments plus tiered royalties Ended the second quarter with a strong financial position with $1.1B in cash, cash equivalents and marketable securities, following completion of $770.5M initial public offering and other transactions, expected to fund operations into 2030 CAMBRIDGE, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) &#8212; Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable &hellip; Continue reading &quot;Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/parabilis-medicines-reports-second-quarter-2026-financial-results-and-provides-business-updates\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-13T11:04:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwOTIyNiM3Nzc0MTI2IzIzMTEyMTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/parabilis-medicines-reports-second-quarter-2026-financial-results-and-provides-business-updates\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/parabilis-medicines-reports-second-quarter-2026-financial-results-and-provides-business-updates\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates\",\"datePublished\":\"2026-08-13T11:04:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/parabilis-medicines-reports-second-quarter-2026-financial-results-and-provides-business-updates\\\/\"},\"wordCount\":2217,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/parabilis-medicines-reports-second-quarter-2026-financial-results-and-provides-business-updates\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwOTIyNiM3Nzc0MTI2IzIzMTEyMTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/parabilis-medicines-reports-second-quarter-2026-financial-results-and-provides-business-updates\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/parabilis-medicines-reports-second-quarter-2026-financial-results-and-provides-business-updates\\\/\",\"name\":\"Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/parabilis-medicines-reports-second-quarter-2026-financial-results-and-provides-business-updates\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/parabilis-medicines-reports-second-quarter-2026-financial-results-and-provides-business-updates\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwOTIyNiM3Nzc0MTI2IzIzMTEyMTM=\",\"datePublished\":\"2026-08-13T11:04:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/parabilis-medicines-reports-second-quarter-2026-financial-results-and-provides-business-updates\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/parabilis-medicines-reports-second-quarter-2026-financial-results-and-provides-business-updates\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/parabilis-medicines-reports-second-quarter-2026-financial-results-and-provides-business-updates\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwOTIyNiM3Nzc0MTI2IzIzMTEyMTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwOTIyNiM3Nzc0MTI2IzIzMTEyMTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/parabilis-medicines-reports-second-quarter-2026-financial-results-and-provides-business-updates\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/parabilis-medicines-reports-second-quarter-2026-financial-results-and-provides-business-updates\/","og_locale":"en_US","og_type":"article","og_title":"Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates - Market Newsdesk","og_description":"Advanced zolucatetide across multiple Wnt\/\u03b2-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors\u00a0 Announced strategic research collaboration with Regeneron to develop Antibody-Helicon Conjugates, expanding application of company&#8217;s proprietary Helicon TM platform; received $125M in upfront consideration and equity investment, with the potential for up to $2.2B in milestone payments plus tiered royalties Ended the second quarter with a strong financial position with $1.1B in cash, cash equivalents and marketable securities, following completion of $770.5M initial public offering and other transactions, expected to fund operations into 2030 CAMBRIDGE, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) &#8212; Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable &hellip; Continue reading \"Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/parabilis-medicines-reports-second-quarter-2026-financial-results-and-provides-business-updates\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-13T11:04:11+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwOTIyNiM3Nzc0MTI2IzIzMTEyMTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/parabilis-medicines-reports-second-quarter-2026-financial-results-and-provides-business-updates\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/parabilis-medicines-reports-second-quarter-2026-financial-results-and-provides-business-updates\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates","datePublished":"2026-08-13T11:04:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/parabilis-medicines-reports-second-quarter-2026-financial-results-and-provides-business-updates\/"},"wordCount":2217,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/parabilis-medicines-reports-second-quarter-2026-financial-results-and-provides-business-updates\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwOTIyNiM3Nzc0MTI2IzIzMTEyMTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/parabilis-medicines-reports-second-quarter-2026-financial-results-and-provides-business-updates\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/parabilis-medicines-reports-second-quarter-2026-financial-results-and-provides-business-updates\/","name":"Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/parabilis-medicines-reports-second-quarter-2026-financial-results-and-provides-business-updates\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/parabilis-medicines-reports-second-quarter-2026-financial-results-and-provides-business-updates\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwOTIyNiM3Nzc0MTI2IzIzMTEyMTM=","datePublished":"2026-08-13T11:04:11+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/parabilis-medicines-reports-second-quarter-2026-financial-results-and-provides-business-updates\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/parabilis-medicines-reports-second-quarter-2026-financial-results-and-provides-business-updates\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/parabilis-medicines-reports-second-quarter-2026-financial-results-and-provides-business-updates\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwOTIyNiM3Nzc0MTI2IzIzMTEyMTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwOTIyNiM3Nzc0MTI2IzIzMTEyMTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/parabilis-medicines-reports-second-quarter-2026-financial-results-and-provides-business-updates\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/994667","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=994667"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/994667\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=994667"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=994667"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=994667"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}